How GLP-1 receptor agonists work can be traced through one receptor and three main tissues. Labels summarize it briefly; cell, animal and human studies show how each effect was measured.
Quick answer: GLP-1 receptor agonists activate the same receptor as the natural hormone GLP-1 but last much longer in the body. FDA labels describe glucose-dependent insulin release, lower glucagon, delayed gastric emptying and reduced appetite. Tirzepatide also activates the GIP receptor. FDA approval applies to specific labeled medicines, not to research material.
What is a GLP-1 receptor agonist?
An agonist is a molecule that binds a receptor and switches it on. These medicines switch on the receptor for glucagon-like peptide-1 (GLP-1), a hormone the gut releases after eating. Vitrapep's article on what GLP-1 is covers the natural hormone.
The Ozempic label describes semaglutide as a GLP-1 analogue with 94% sequence homology to human GLP-1. It says semaglutide "selectively binds to and activates the GLP-1 receptor" (section 12.1).
Most medicines in the class are peptides. Not all are. The Foundayo label says orforglipron, a small molecule first approved in 2026, "binds to and activates the human GLP-1 receptor." Vitrapep's list of FDA-approved peptide medicines covers the peptide members.
The medicines differ from the hormone mainly in how long they last. The Ozempic label names albumin binding as the main reason, plus stabilization against the enzyme DPP-4. The Mounjaro label says tirzepatide's C20 fatty diacid "enables albumin binding and prolongs the half-life."
What is the GLP-1 receptor and where is it found?
In 1992, a University of Lausanne study cloned the receptor from rat pancreatic islets. Expressed in cultured cells, it bound GLP-1 with high affinity but did not bind glucagon, GIP or secretin (Thorens, 1992).
The receptor is 463 amino acids long and crosses the cell membrane seven times. Activating it switched on adenylate cyclase, the enzyme that makes cyclic AMP (cAMP). It belongs to a family of G-protein-coupled receptors that includes the secretin, calcitonin and parathyroid hormone receptors.
A 2014 study led by Novo Nordisk scientists mapped the receptor in monkey and human tissue (Pyke et al., 2014). It reported these sites.
- Pancreas: mainly beta cells, with a weaker signal in acinar cells.
- Gut: highest in Brunner's glands of the duodenum, lower in the stomach and in gut-wall nerve cells.
- Heart: muscle cells of the sinoatrial node, the heart's natural pacemaker.
- Kidney and lung: smooth muscle in the walls of small arteries.
- No receptor was seen in primate liver or thyroid.
The brain is the other major site. The Wegovy label says the receptor "is present in several areas of the brain involved in appetite regulation."
What happens inside a cell when the receptor is switched on?
The receptor converts an outside signal into rising cAMP inside the cell. In beta cells, that signal works together with glucose rather than replacing it.
A 1993 study in rat beta cells showed how. Beta cells that did not respond to glucose became responsive with GLP-1. The authors called this "glucose competence" (Holz et al., 1993).
GLP-1 and glucose acted together to close potassium channels controlled by cell metabolism. Sulfonylurea drugs block the same channels. Closing them let calcium flow in, which triggers insulin release. This joint requirement is the cell-level basis for the "glucose-dependent" wording on labels.
The receptor can also recruit proteins called beta-arrestins, which are linked to pulling the receptor inside the cell. Agonists can favor one pathway over another, which researchers call biased agonism. Tirzepatide is a studied example.
How do GLP-1 receptor agonists affect insulin and glucagon?
The Ozempic label says semaglutide stimulates insulin and lowers glucagon, "both in a glucose-dependent manner." When glucose is high, insulin secretion is stimulated and glucagon secretion is inhibited.
A 1993 human study showed what glucose dependence looks like. In a placebo-controlled design, 10 adults with poorly controlled type 2 diabetes received GLP-1 or placebo while fasting (Nauck et al., 1993). With GLP-1, insulin rose, glucagon fell and glucose reached normal fasting levels within four hours.
Once glucose was normal, insulin returned toward baseline and glucose stayed stable while GLP-1 was still being given. Placebo did not normalize glucose.
In the Ozempic label's type 2 diabetes data, fasting glucagon was 8% lower than with placebo. The post-meal glucagon response was 14 to 15% lower. During induced low blood sugar, semaglutide did not blunt the protective rise in glucagon.
Low blood sugar can still occur. The label warns of increased hypoglycemia risk, including severe hypoglycemia, when semaglutide is combined with insulin or a sulfonylurea.
Animal genetics support the receptor's role. Mice bred without it had higher glucose and lower insulin after an oral glucose challenge (Scrocchi et al., 1996).
How do they affect the stomach and gut?
GLP-1 receptor activation slows how fast food leaves the stomach. The Ozempic label counts "a minor delay in gastric emptying in the early postprandial phase" as part of how semaglutide lowers glucose.
The effect weakens with continued exposure. A 2011 study gave nine healthy volunteers GLP-1 or placebo over 8.5 hours (Nauck et al., 2011). Two liquid meals were served four hours apart. GLP-1 slowed emptying significantly more after the first meal than the second.
Pancreatic polypeptide, a marker of vagus nerve activity, fell after the first meal only. The authors concluded that the slowing fades rapidly at the level of vagal signaling, called tachyphylaxis. Glucose control after the second meal was weaker as a result.
The Mounjaro and Foundayo labels report a similar pattern: the delay is largest at the start of treatment and diminishes over time.
The effect also appears in label safety sections. The Ozempic label links delayed emptying to rare reports of pulmonary aspiration during general anesthesia or deep sedation. Those patients had food left in the stomach.
How do they act on the brain and appetite?
Human studies link GLP-1 to fullness and lower food intake. In a 1998 randomized, blinded crossover study, 20 healthy young men received GLP-1 or saline during test meals (Flint et al., 1998). GLP-1 increased satiety after a fixed breakfast and cut energy intake at a free-choice lunch by 12%.
Labels place this effect in the brain but rely on animal data for that step. The Wegovy label says animal studies show semaglutide "distributed to and activated neurons in brain regions involved in regulation of food intake." The Foundayo label says the same of orforglipron.
A 2014 rodent study traced one pathway (Secher et al., 2014). In mice, labeled liraglutide reached brain areas with a weaker blood-brain barrier. It bound neurons in the hypothalamic arcuate nucleus, and uptake required the GLP-1 receptor.
In mouse brain slices, GLP-1 directly stimulated neurons making POMC and CART, signals linked to fullness. It indirectly inhibited neurons making NPY and AgRP, signals linked to hunger. In rats, weight loss did not depend on receptors in the vagus nerve or area postrema.
In contrast, mice lacking the receptor had normal body weight and feeding (Scrocchi et al., 1996). Losing a natural signal and adding a long-acting agonist are different experiments.
Vitrapep's semaglutide mechanism article covers newer brain research.
Which findings come from cells, animals and people?
Table 1 sorts the studies above by evidence level.
Which findings come from cells, animals and people
| Study | Evidence level | Model and size | Main finding |
|---|---|---|---|
| Thorens, 1992 | Cell | Rat receptor in cultured cells | Seven-pass receptor coupled to adenylate cyclase |
| Holz et al., 1993 | Cell | Rat beta cells | GLP-1 plus glucose closed potassium channels |
| Nauck et al., 1993 | Human | 10 adults with type 2 diabetes | Fasting glucose normalized; insulin fell back once it did |
| Scrocchi et al., 1996 | Animal | Mice lacking the receptor | Glucose intolerance; normal weight and feeding |
| Flint et al., 1998 | Human | 20 healthy men, crossover | 12% lower energy intake at lunch |
| Nauck et al., 2011 | Human | 9 healthy volunteers | Gastric slowing weaker after a second meal |
| Pyke et al., 2014 | Tissue | Monkey and human tissue | Receptor in beta cells, sinoatrial node, arteries and gut |
| Secher et al., 2014 | Animal | Rats and mice | Liraglutide reached arcuate nucleus neurons |
What do FDA labels say about each medicine's mechanism?
Section 12.1 of each label is the mechanism of action, and 12.2 is pharmacodynamics. Table 2 compares four current labels.
What do FDA labels say about each medicine's mechanism
| Label (ingredient) | Molecule | Receptors | Other mechanism statements | Gastric emptying |
|---|---|---|---|---|
| Ozempic (semaglutide) | Peptide; albumin binding | GLP-1 | Glucose-dependent insulin and glucagon effects; kidney-risk mechanism not established | Minor delay soon after meals |
| Wegovy (semaglutide) | Same molecule | GLP-1 | Receptor in brain appetite areas; cardiovascular-risk mechanism not established | Delayed |
| Mounjaro (tirzepatide) | Peptide with C20 fatty diacid | GIP and GLP-1 | First- and second-phase insulin enhanced; glucagon reduced | Largest at the start, then diminishes |
| Foundayo (orforglipron) | Small molecule | Human GLP-1 | Brain appetite regions; animal neuron data | Largest at the start, then diminishes |
How is tirzepatide's mechanism different?
Tirzepatide activates two receptors. The Mounjaro label says it activates "both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1" (section 12.1). GIP is the gut's second main incretin hormone.
A 2020 study by Eli Lilly scientists and academic partners measured how tirzepatide engages each receptor (Willard et al., 2020). Their occupancy estimates showed greater engagement of the GIP receptor, which they called an imbalanced profile.
At the GLP-1 receptor, tirzepatide favored cAMP production over beta-arrestin recruitment and drove less receptor internalization than GLP-1. In isolated islets, beta-arrestin 1 limited the insulin response to GLP-1 but not to tirzepatide. These are cell and tissue findings, and most authors were company employees.
See Vitrapep's tirzepatide mechanism article, tirzepatide complete guide and semaglutide complete guide for each molecule's trials.
Which side effects connect to the mechanism?
Labels list mostly digestive reactions. The Ozempic label lists nausea, vomiting, diarrhea, abdominal pain and constipation in at least 5% of patients. The Mounjaro label lists nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia and abdominal pain.
In placebo-controlled trials, Mounjaro raised mean heart rate by 2 to 4 beats per minute, versus 1 on placebo. The primate receptor map found the receptor in the sinoatrial node, but the labels do not state a cause.
All four labels in Table 2 carry a boxed warning about thyroid C-cell tumors in rodents. A 2010 study found the receptor on rodent C-cells, where agonists raised calcitonin and caused C-cell overgrowth (Bjerre Knudsen et al., 2010). Primate C-cells had low receptor levels and released no calcitonin in response. Long-term effects in the human thyroid remain unknown, the authors wrote.
Orforglipron is not pharmacologically active in rats or mice and did not produce rodent tumors, according to its label. That label still says human relevance "has not been determined" for these receptor-dependent tumors.
In November 2026, FDA required a class-wide warning about NAION, a rare optic nerve condition (see FDA's GLP-1 eye-risk warning).
What is still unknown, and how does research material fit?
The Ozempic label says the mechanism of kidney-related risk reduction has not been established. The Wegovy label says the same for cardiovascular risk reduction.
FDA approval covers specific labeled products, and the statements above apply only to them. Research-grade material has no FDA-approved labeling. A research-use-only label does not make a compound legal or safe for people; see research peptides and human-use risks.
Frequently asked questions
Is a GLP-1 receptor agonist the same as GLP-1?
No. GLP-1 is a natural gut hormone. A GLP-1 receptor agonist is a medicine that activates the same receptor and lasts much longer.
Are all GLP-1 receptor agonists peptides?
No. Most are peptides, but orforglipron (Foundayo) is a small molecule that activates the human GLP-1 receptor.
Why is the insulin effect called glucose-dependent?
GLP-1 signaling amplifies insulin release when glucose is high. In a 1993 human study, insulin fell back toward baseline once glucose was normal.
Does the slowing of stomach emptying last?
It fades. A 2011 study found the delay weaker after a second meal, and two labels say it diminishes over time.
Do these medicines act directly on the brain?
Labels say GLP-1 receptors are present in appetite-regulating brain areas. Evidence that the medicines reach those neurons comes from animal studies.
Why do the labels carry a thyroid warning?
Rodent studies found receptor-dependent thyroid C-cell tumors. Primate C-cells have low receptor levels, but human relevance has not been determined.
What to know now
- GLP-1 receptor agonists raise insulin and lower glucagon when glucose is elevated.
- They slow stomach emptying, but the effect fades with continued exposure.
- Direct brain action is shown in animals; human studies show lower food intake with GLP-1.
What we’re watching
- Human studies that separate brain, gut and vagal nerve contributions to appetite changes.
- Research on the mechanisms behind the cardiovascular and kidney outcomes named in labels.
- Whether biased signaling at the GLP-1 receptor matters for clinical effects.